Translational 'omics and biomarkers group

The genetic diversity on a single human chromosome reaches 50%. A consequence of such diversity is that people are physiologically and phenotypically different, carry different risks for developing diseases and pharmacologically respond differently. The Translational 'Omics and Biomarkers Group uses a multi-disciplinary approach to profile and sub-type diseases and populations, and on doing so discover new biomarkers, identify mechanisms and novel druggable targets. 

Our strategy is to use a patient-oriented approach and broadly profiling the samples using post-genomics mass-spectrometry platforms to obtain quantitative (patho)physiological data. Applying multivariate statistical analyses and a touch of biological knowledge, we zoom in plausible targets associated with a disease and its sub-types. Guided by these information, we do two things - 1) validate the targets as biomarkers in independent patient cohorts, and 2) test hypotheses in physiologically relevant experimental models using a combination of biochemical and molecular biology techniques as well as state-of-art imaging and mass spectrometry. From (1) the knowledge can reveal new mechanisms, improve health outcomes using existing treatments, and inform drug development. From (2), we begin to uncover new druggable targets and opens up new avenues for therapeutic intervention. We collaborate widely to answer some of the most difficult questions in benign gynaecology and infectious diseases.